Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in May 2008*Drugs may be covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
HABITROL
Novartis
nicotine
5,016,652
May 21, 2008
REQUIP
Glaxosmithkline
ropinirole hydrochloride
4,824,860
May 19, 2008
SARAFEM
Lilly
fluoxetine hydrochloride
4,971,998
May 20, 2008
Courtesy of DrugPatentWatch.com
Original post by BiotechBlog
Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions.
For those of you attending BIO 2008, I’ll be presenting in a session on trends in [...]
The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:
Volume 14, Issue 2
Editorial
Yali Friedman
A new approach to improve technology commercialisation in university medical schools
Courtney Price, Richard Huston and Arlen D Meyers
Export compliance for life sciences
John Avellanet
(more…)
Original [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in April 2008*Drugs may be covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
ACTINEX
Univ Az Cancer Ctr
masoprocol
4,695,590
APR 17,2008
ACTINEX
Univ Az Cancer Ctr
masoprocol
5,008,294
APR 15,2008
ESTROSTEP 21
Warner Chilcott
ethinyl estradiol; norethindrone acetate
5,010,070
APR 23,2008
ESTROSTEP FE
Warner Chilcott
ethinyl estradiol; norethindrone acetate
5,010,070
APR 23,2008
FEMPATCH
Parke Davis
estradiol
5,006,342
APR 09,2008
LODINE XL
Wyeth Pharms Inc
etodolac
4,966,768
APR 30,2008
ORFADIN
Swedish Orphan
nitisinone
5,006,158
APR 09,2008
ZEMURON
Organon Usa Inc
rocuronium bromide
4,894,369
APR 13,2008
Courtesy of DrugPatentWatch.com
Original post [...]
Posting has been light lately — I’ve been working hard on revising Building Biotechnology.
Off to the NIH next week to give my talk on biotechnology entrepreneurship.
Upcoming talk at Johns Hopkins Carey School of Business on a multifaceted dissection of the biotechnology industry.
Original post by BiotechBlog
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in March 2008*Drugs may be covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
CARDIZEM CD
Biovail
diltiazem hydrochloride
5,002,776
MAR 26,2008
CARDURA XL
Pfizer
doxazosin mesylate
4,837,111
MAR 21,2008
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
Bayer Pharms
ciprofloxacin
4,957,922
MAR 18,2008
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Bayer Pharms
ciprofloxacin
4,957,922
MAR 18,2008
ESCLIM
Women First Hlthcare
estradiol
4,842,864
MAR 25,2008
IFEX
Bristol Myers Squibb
ifosfamide
4,882,452
MAR 03,2008
IFEX/MESNEX KIT
Bristol Myers Squibb
ifosfamide; mesna
4,882,452
MAR 03,2008
NEXIUM
Astrazeneca
esomeprazole magnesium
4,738,974
MAR 01,2008
NEXIUM
Astrazeneca
esomeprazole magnesium
4,783,974
MAR [...]
Two new biotechnology books:
I’m proud to announce two new books featuring international best practices in biotechnology business development and biotechnology education. These new books respectively empower industry leaders operating in the dynamic biotechnology industry, and help address the global shortage of skilled biotechnology workers.
First Edition, March 2008
Perfect Bound, 342 pages, US$74.95
ISBN: 978-09734676-7-3
Homepage
Amazon
Best Practices [...]
Guest content from John Avellanet, managing director and principal of Cerulean Associates:
Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete.
Science Succumbs to Dollars
The financial pull on reimbursement organizations and the constituent push [...]
Browsing around the Biotechnology Industry Organization site late last night, I was surprised to find that BIO’s press release section had been hacked. No evidence of tampering elsewhere on the site, but all the news releases have been tagged by the hackers.
Original post by BiotechBlog
I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular notions about how biotechnology entrepreneurship occurs, and to provide case studies demonstrating the diversity of methods by which biotechnology entrepreneurs start and build their businesses. I’ll also provide some case studies of significant [...]
The following appeal for generic biologic legislation was sent in from Insmed via youtube.
I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the [...]
Two new biotechnology books due out in March 2008:
First Edition, March 2008
Perfect Bound, 340 pages, US$74.95
ISBN: 978-09734676-7-3
Best Practices in Biotechnology Education
22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups
Best Practices in Biotechnology Education is directed at faculty seeking to start or expand biotechnology education programs; policy-makers [...]
On returning from a meeting with a small biotechnology firm in which I serve on the advisory board, I was reminded of a novel strategy for attracting venture capital.
One of the challenges is attracting investment is finding an investor aligned with your company’s future directions. Venture capitalists may be interested only in large companies, [...]
After months of work, the issue of the Journal of Commercial Biotechnology I’ve edited has just been published. Better yet, it’s available online for free. The links below will take you to the full text of each article:
Volume 14, Issue 1
Editorial
Yali Friedman
Bioentrepreneurship education programmes in the United States
Arlen D Meyers and Patrick Hurley
The ability [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in January 2008*Drugs may be
covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
CARDIOLITE
Bristol Myers Squibb
technetium tc-99m sestamibi kit
4,988,827
JAN 29,2008
CHILDREN’S ADVIL
Wyeth Cons
ibuprofen
4,788,220
JAN 08,2008
COVERA-HS
Gd Searle Llc
verapamil hydrochloride
5,200,196
JAN 22,2008
DEPAKOTE
Abbott
divalproex sodium
4,988,731
JAN 29,2008
DEPAKOTE
Abbott
divalproex sodium
5,212,326
JAN 29,2008
DEPAKOTE CP
Abbott
divalproex sodium
4,988,731
JAN 29,2008
DEPAKOTE CP
Abbott
divalproex sodium
5,212,326
JAN 29,2008
DEPAKOTE ER
Abbott
divalproex sodium
4,988,731
JAN 29,2008
DEPAKOTE ER
Abbott
divalproex sodium
5,212,326
JAN 29,2008
METROGEL-VAGINAL
Graceway
metronidazole
5,840,744
JAN 15,2008
MIRALUMA
Bristol Myers Squibb
technetium tc-99m sestamibi kit
4,988,827
JAN 29,2008
TECZEM
Biovail
diltiazem malate; enalapril [...]
My recent presentation at the “Biotechnology for Turkey” conference has been posted online. My central thesis was that the challenges faced by Turkey (and most any other location) are shared by many states within the United States. I’ve heard too many people opine for the seemingly easy start-up environment in the United States. The [...]
Guest content from John Avellanet, managing director of Cerulean Associates:
The US Food and Drug Administration (FDA) intends to increase regulatory enforcement, extending the recent trend of laboratory and clinical site inspections to unapproved drugs and reformulations. How can you avoid compliance trouble?
At the Food and Drug Law Institute’s 5th Annual Enforcement and Litigation [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in December 2007*Drugs may be
covered by multiple patents
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
DOVONEX
Leo Pharm
calcipotriene
4,866,048
DEC 29,2007
FASLODEX
Astrazeneca
fulvestrant
4,659,516
DEC 11,2007
KYTRIL
Roche
granisetron hydrochloride
4,886,808
DEC 20,2007
KYTRIL
Roche
granisetron hydrochloride
4,886,808
DEC 29,2007
MERIDIA
Abbott
sibutramine hydrochloride
4,746,680
DEC 11,2007
REQUIP
Glaxosmithkline
ropinirole hydrochloride
4,452,808
DEC 07,2007
TACLONEX
Leo Pharm Prods
betamethasone dipropionate; calcipotriene hydrate
4,866,048
DEC 29,2007
ZINECARD
Pharmacia And Upjohn
dexrazoxane hydrochloride
4,963,551
DEC 21,2007
ZYRTEC
Pfizer
cetirizine hydrochloride
4,525,358
DEC 25,2007
ZYRTEC-D 12 HOUR
Pfizer
cetirizine hydrochloride; pseudoephedrine hydrochloride
4,525,358
DEC 25,2007
Courtesy of DrugPatentWatch.com
Original post by BiotechBlog
At a recent event was recently asked about investment outcomes for venture capitalists. I didn’t have any recent data, so I said that VCs generally expect that 1/3 of their investments will see great returns, 1/3 will see modest or no returns, and 1/3 will not be profitable.
VC Fred Wilson as Union Square Ventures [...]
I’ll be giving a talk on “Career Development in Biotechnology” next week in the AstraZeneca seminar series at the University of Toronto. More details are available at the MBiotech website.
Original post by BiotechBlog
Bio-Rad’s got an interesting website up: RethinkPCR.
The company’s name isn’t posted on the front page, but is readily available in the contest terms and conditions and privacy policy. It’s an interesting strategy to acquire consumer intelligence. Of course, consumers don’t always ask for what they want — they tend to ask for incremental improvements [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in November 2007*Drugs may be covered by more than one patent
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
ANDRODERM
Watson Labs
testosterone
4,849,224
NOV 12,2007
ANDRODERM
Watson Labs
testosterone
4,983,395
NOV 12,2007
AVITA
Mylan Bertek
tretinoin
4,971,800
NOV 20,2007
COMTAN
Orion
entacapone
4,963,590
NOV 27,2007
ELOCON
Schering
mometasone furoate
4,775,529
NOV 21,2007
FLECTOR
Inst Biochem
diclofenac epolamine
4,948,805
NOV 09,2007
MERIDIA
Abbott
sibutramine hydrochloride
4,929,629
NOV 29,2007
MYLOTARG
Wyeth Pharms Inc
gemtuzumab ozogamicin
4,970,198
NOV 30,2007
PROVIGIL
Cephalon
modafinil
4,927,855
NOV 22,2007
STALEVO 100
Orion
carbidopa; entacapone; levodopa
4,963,590
NOV 27,2007
STALEVO 150
Orion
carbidopa; entacapone; levodopa
4,963,590
NOV 27,2007
STALEVO 50
Orion
carbidopa; entacapone; levodopa
4,963,590
NOV 27,2007
TOPROL-XL
Astrazeneca
metoprolol succinate
4,927,640
NOV 22,2007
TYLENOL (CAPLET)
Mcneil Cons
acetaminophen
4,968,509
NOV [...]
Today marks the 25th anniversary of the FDA’s approval of the first drug produced by biotechnology, Genentech’s Humulin. I often use Humulin as a case study for biotechnology, because Genentech’s bacterial-fermentation approach to making insulin was revolutionary compared to the previous methods of harvesting insulin from pig pancreas.
Thanks for OpenMarket for reminding me of [...]
I’ve been waiting to write up the Exubera story for the next edition of Building Biotechnology, and the story just keeps getting better.
Exubera is was Pfizer’s innovative answer to the diabetes drug market. The market is so saturated with competitive products, that the only way to capture significant market share is to innovate. Either [...]
I’ll be speaking at the Biotech for Turkey conference in Istanbul on November 7th. This conference, convened by Bosfor Biotech Partners, will cover global biotechnology strategies and developments in Turkey. For more details, contact Bosfor Biotech at the URL above or browse the conference schedule: Biotech for Turkey
Original post by BiotechBlog
Journal of Commercial Biotechnology - Special Issue on Product Innovation Management and Marketing
Focus of the Special Issue
Biotechnology companies are product innovation firms, yet they face a collection of challenges which make it inappropriate to simply apply existing innovation management thinking. For instance, at present relatively few biotechnology firms generate earned income from sales. [...]
A new issue of the Journal of Commercial Biotechnology has just been posted. Drop me a line if you would like to make a submission.
Volume 13, Issue 4
Is ‘evergreening’ a cause for concern? A legal perspective
Scott Parker and Kevin Mooney
Exploiting the business opportunities in biotech connections: The power of social networks
Ian P McCarthy, Leyland [...]
Wired has an article on the potential for the pharmaceutical industry to support the international space station, using the microgravity environment to grow better quality crystals than can be grown on earth, in less time.
Protein crystals can be used to improve drug discovery, but the distance from crystal to drug is very long. Much [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in October 2007*Drugs may be covered by more than one patent
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
CLARINEX
Schering
desloratadine
4,659,716
OCT 01,2007
CLARINEX
Schering Plough
desloratadine
4,659,716
OCT 01,2007
CLARINEX D 24 HOUR
Schering
desloratadine; pseudoephedrine sulfate
4,659,716
OCT 01,2007
CLARINEX-D 12 HOUR
Schering
desloratadine; pseudoephedrine sulfate
4,659,716
OCT 01,2007
COVERA-HS
Gd Searle Llc
verapamil hydrochloride
4,946,687
OCT 02,2007
DYNACIRC CR
Reliant Pharms
isradipine
4,816,263
OCT 02,2007
DYNACIRC CR
Reliant Pharms
isradipine
4,946,687
OCT 02,2007
DYNACIRC CR
Reliant Pharms
isradipine
4,950,486
OCT 02,2007
ESTROSTEP 21
Warner Chilcott
ethinyl estradiol; norethindrone acetate
4,962,098
OCT 09,2007
ESTROSTEP FE
Warner Chilcott
ethinyl [...]
On the same day that AstraZeneca has announced that it intents to completely outsource all of its drug manufacturing, citing the prevalence of external parties who can do it better and cheaper, Sanofi has announced plans toIf you understand the rules and strategies of free blackajck online it won’t be difficult for you. increase [...]
I’ll be attending the Mid-Atlantic Bio in Bethesda in late October.
On November 8th I’ll be in Turkey speaking at the Biotechnology for Turkey Conference.
I’ll be in Toronto in late November, speaking in the AstraZeneca speaker series at the University of Toronto.
If you’re interested in more details or want to meet up, drop me a [...]
With the start of a new school year, a new cohort of students are entering biotechnology programs. In order to facilitate those who are using my book, Building Biotechnology, I have set up a networking and information group on facebook.
I’m always interested in tracking the outcomes of students in biotechnology programs. If you’re [...]
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in September 2007*Drugs may be covered by more than one patent
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
BETAXON
Alcon
levobetaxolol hydrochloride
4,911,920
SEP 27,2007
BETOPTIC S
Alcon
betaxolol hydrochloride
4,911,920
SEP 27,2007
CARDIOLITE
Bristol Myers Squibb
technetium tc-99m sestamibi kit
4,885,100
SEP 11,2007
COGNEX
Sciele Pharma Inc
tacrine hydrochloride
4,816,456
SEP 09,2007
COREG
Smithkline Beecham
carvedilol
4,503,067
SEP 05,2007
COREG CR
Sb Pharmco
carvedilol phosphate
4,503,067
SEP 05,2007
MIRALUMA
Bristol Myers Squibb
technetium tc-99m sestamibi kit
4,885,100
SEP 11,2007
NEXIUM
Astrazeneca
esomeprazole magnesium
4,738,974
SEP 01,2007
PENLAC
Sanofi Aventis Us
ciclopirox
4,957,730
SEP 18,2007
PULMICORT
Astrazeneca
budesonide
4,907,583
SEP 13,2007
TECZEM
Biovail
diltiazem malate; enalapril [...]
Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again.
A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents.
I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely different [...]
The FDA approved 38 drugs through July this year, down 31 percent from 55 approvals for the same period last year.
Who’s to blame? According to Friedman, Billings, Ramsey, the FDA. Why? Vioxx.
For details on extra scrutiny being applied by the FDA, see this CNNMoney summary.
Original post by BiotechBlog
